Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.

Front Oncol · 2022 · PMC9885011 · PMID 36727075

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Those with higher tumor-infiltrating CD3 + and CD8 + T cells showed a trend toward improved OS (both p = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.